Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC screening strategy across modeled age ranges and screening ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

This approach contributed to strong growth in Cologuard test utilization among rescreen patients and within care gap programs during the third quarter. Exact Sciences received FDA approval for the ...